The Parkinson’s Disease Therapeutic Market Size is valued at USD 4.22 billion in 2023 and is predicted to reach USD 6.51 billion by the year 2031 at a 5.7% CAGR during the forecast period for 2024-2031.
Parkinson's disease is attributed to the loss of neurons in the part of the brain responsible for motor control. The exact etiology of nerve cell degeneration remains unknown; however, it is hypothesized that exposure to environmental risk factors and genetic predisposition may play a significant role. The Parkinson's disease Therapeutic Market is witnessing robust growth, propelled by numerous key drivers and emerging opportunities.
The Parkinson's disease therapeutic market is a dynamic sector focused on developing treatments to manage the symptoms and progression of this neurodegenerative disorder. It encompasses a range of pharmaceuticals, medical devices, and therapies aimed at quality improvement of life for individuals with Parkinson's disease. Supportive care, including counselling and educational resources, is essential for both patients and caregivers. Although there is presently no remedy for Parkinson's disease, implementing these comprehensive techniques can greatly improve quality of life and effectively manage symptoms.
The overall market players consist of pharmaceutical companies, research institutions, and healthcare providers. Advances in research and technology drive innovation in treatment options, with a growing emphasis on personalized medicine and holistic approaches to care. Despite challenges such as regulatory hurdles and limited treatment options, the market continues to evolve to meet the needs of patients worldwide.
Some Major Key Players In The Parkinson’s Disease Therapeutic Market:
The Parkinson's disease therapeutic market is categorized on the basis of drug class, distribution channel, brand and route of administration. According to the drug class, the market is segmented into carbidopa-levodopa, dopamine agonists, Mao-b inhibitors, COMT inhibitors, anticholinergics, and others. As per the distribution channel, the market is divided into hospital pharmacy, retail pharmacy, and online pharmacy.
The dopamine agonists segment in the Parkinson's disease therapeutic market comprises a class of medications that mimic the action of dopamine in the brain to alleviate motor symptoms of the disease. These drugs stimulate dopamine receptors, helping to improve movement control and reduce tremors and rigidity in patients with Parkinson's disease. Common dopamine agonists include pramipexole and ropinirole. While effective in managing symptoms, these medications may also be associated with side effects such as nausea, dizziness, and hallucinations. Despite challenges, dopamine agonists play a crucial role in the treatment regimen for many individuals living with Parkinson's disease.
The hospital pharmacy segment of the Parkinson's disease therapeutic market focuses on providing medications and pharmaceutical services within hospital settings to manage the complex treatment needs of patients with Parkinson's disease. Hospital pharmacies play a important role in ensuring the availability, proper dosing, and administration of medications such as levodopa, dopamine agonists, and other therapies used to alleviate symptoms & improve the quality of life for individuals with Parkinson's disease. These pharmacies also collaborate with healthcare teams to monitor drug interactions, adjust treatment regimens, and optimize medication adherence to enhance patient outcomes and safety during hospitalization and post-discharge care.
The North American Parkinson's disease therapeutic market is a significant sector characterized by a high prevalence of the disease and a strong focus on research, innovation, and healthcare infrastructure. The region comprises leading pharmaceutical companies, research institutions, and healthcare providers dedicated to developing and delivering advanced treatments for Parkinson's disease. With a growing ageing population and increasing awareness of neurological disorders, the market in North America continues to expand, offering various medications, therapies, and support services to direct the complex needs of patients. Ongoing advancements in treatment options and patient care contribute to shaping the landscape of Parkinson's disease management in North America. Asia Pacific is counted to grow at a rapid rate in the global Parkinson's disease Therapeutic Market due to growing concerns about rapid industrialization, government initiatives, and increasing funding in various industries.
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 4.22 Bn |
|
Revenue Forecast In 2031 |
USD 6.51 Bn |
|
Growth Rate CAGR |
CAGR of 5.7% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Drug Class, Distribution Channel, Brand And Route Of Administration |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; Southeast Asia; South Korea |
|
Competitive Landscape |
Teva Pharmaceutical Industries Ltd., Novartis AG, GlaxoSmithKline Plc., AbbVie Inc., Merck & Co., Inc., Zydus Cadila, Dr. Reddy's, Sun Pharmaceutical Industries Ltd., Cipla Inc., Boehringer Ingelheim International GmbH, Denali Therapeutics Inc., Biogen Inc., Prevail Therapeutics and Others |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Parkinson's Disease Therapeutic Market By Drugs
Parkinson's Disease Therapeutic Market By Distribution Channel-
Parkinson's Disease Therapeutic Market By Brand
Parkinson's Disease Therapeutic Market By Route of Administration
Parkinson's Disease Therapeutic Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
